Form 8-K - Current report:
SEC Accession No. 0001213900-25-028621
Filing Date
2025-04-03
Accepted
2025-04-03 16:15:09
Documents
13
Period of Report
2025-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0237095-8k_citius.htm   iXBRL 8-K 26969
  Complete submission text file 0001213900-25-028621.txt   202903

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ctor-20250328.xsd EX-101.SCH 3017
3 XBRL LABEL FILE ctor-20250328_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE ctor-20250328_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0237095-8k_citius_htm.xml XML 3766
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-41534 | Film No.: 25809636
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)